-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 17th, Shanghai Pharmaceuticals issued an announcement stating that rosuvastatin calcium tablets of Shanghai Pharmaceutical Xinyi, a wholly-owned subsidiary of Shanghai Pharmaceuticals, received the "Drug Registration Certificate" issued by the State Food and Drug Administration, and the drug was approved for production
Rosuvastatin calcium tablets are mainly used for the treatment of primary hypercholesterolemia (type IIa, including heterozygous familial) that cannot properly control dyslipidemia after diet control and other non-drug treatments (such as exercise therapy, weight loss) Hypercholesterolemia) or mixed dyslipidemia (type IIb)